Drug intelligence / Profile preview

adamastat

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous

Overview

Adamastat is a novel ADAM15-specific sulfonamide inhibitor designed to target A disintegrin and metalloproteinase domain-containing protein 15 (ADAM15). ADAM15 is a metalloproteinase that plays a role in tumor progression by shedding membrane-bound growth factors and cleaving cell adhesion molecules. Adamastat has demonstrated bioactivity, significantly reducing the viability of bladder cancer cells in vitro and inhibiting tumor growth in human bladder cancer xenografts, suggesting its potential as a therapeutic agent for advanced bladder cancer.

Targets

ADAM15

Beyond the preview

Go deeper on adamastat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adamastat.

Explore the full profile